Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2437293 | 1.00 | TAAR1 (0.59) | TAAR1MTNR1AMTNR1BAOC3LMNA | |
| SCHEMBL30800373 | 0.85 | MTNR1A (0.60) | TAAR1MTNR1AMTNR1BAOC3CASP3 | |
| SCHEMBL7331644 | 0.85 | MTNR1A (0.60) | TAAR1MTNR1AMTNR1BAOC3CASP3 | |
| SCHEMBL4684928 | 0.85 | CA12 (0.55) | MTNR1ALMNASMN1; SMN2CA12CA1 | |
| SCHEMBL3065637 | 0.85 | MTNR1A (0.52) | TAAR1MTNR1AMTNR1BLMNASMN1; SMN2 | |
| SCHEMBL4685285 | 0.84 | L3MBTL1 (0.54) | MTNR1ALMNA | |
| SCHEMBL29590071 | 0.84 | LMNA (0.59) | TAAR1MTNR1AMTNR1BLMNASMN1; SMN2 | |
| SCHEMBL266525 | 0.84 | MTNR1A (0.63) | TAAR1MTNR1AMTNR1BLMNACASP3 | |
| SCHEMBL30365164 | 0.84 | MTNR1A (0.63) | TAAR1MTNR1AMTNR1BLMNACASP3 | |
| SCHEMBL362209 | 0.84 | LMNA (0.59) | TAAR1MTNR1AMTNR1BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250366472-A1 | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID OXIDASE INHIBITORS (ACO-I) | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2025-12-04 | — | — | US | disclosed |
| CN-120717925-A | Preparation method of key intermediate of macrocyclic ghrelin receptor modulator | 昆明理工大学 | 2025-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250366472-A1 | 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID OXIDASE INHIBITORS (ACO-I) | DAO, ACOX1, HAO1 | TAAR1 775/4885MTNR1A 2900/4885MTNR1B 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.